Support throughout the patient treatment journey

FREEDOM OF CHOICE™ free-trial program

Your patients may be eligible to receive 6 free-trial doses of ADVATE with the FREEDOM OF CHOICE trial program. The free-trial program is for new patients only. Participants must receive consultation and approval from their healthcare provider.

download form

Hematology Support Center

Takeda's Hematology Support Center (HSC) is a dedicated team to help patients who have been prescribed Takeda hematology products with information, guidance, and resources regarding their treatment.

Visit Hematologysupport.com

If you have patients that have been prescribed ADVATE, here are a few ways that the HSC can help:

Case Managers

Case Managers are a patient's first point of contact. They can assist with CoPay enrollment and will connect patients to other HSC team members if additional information is required.

CoPay Assistance

For eligible commercially insured Takeda patients, Takeda's CoPay assistance program may cover 100% of eligible out-of-pocket expenses related to a patient's Takeda Hematology treatment for which there is a co-pay, such as deductibles and coinsurances, up to the program maximum.^†

Patient Access Manager (PAMs)

Patient Access Managers are insurance experts who are trained to help address potential access challenges with Takeda prescribed treatment. PAMs can:

Provide insurance and access education tools
Help answer questions about insurance access and coverage
Address complex coverage issues, such as a loss or lapse in insurance coverage

Educational Tools and Resources

Insurance education resources are available to help patients understand insurance and the evolving healthcare landscape. Additionally, HSC connects patients and caregivers with community resources and additional tools available for those living with a bleeding disorder. Healthcare Educators are also a part of the HSC team and are fluent in both Spanish and English. They can provide one-on-one education to caregivers and patients on managing their condition.

IMPORTANT NOTICE

^†The Hematology Support Center Copay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 888-229-8379. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.

Resources for your patients

Goals worksheet

This worksheet can help patients track their ABR progress and start their journey striving toward zero bleeds.

Download worksheet

Bleed and infusion tracker

This tool can help patients track their bleeds and infusions so they can stay on top of their treatment management.

Download worksheet

ADVATE Stay the Course Brochure

ADVATE patients seeking encouragement to stay the course can reference this brochure, which contains helpful disease state education, product information, and supportive tips.

Download brochure

ADVATE Patient Profile

This brochure highlights Ezra, a real ADVATE patient, and how he manages his hemophilia A and stays dedicated to his factor regimen.

Download brochure

ADVATE Important Information

Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

Control and prevention of bleeding episodes.
Perioperative management.
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

Patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with ADVATE. Symptoms include dizziness, paresthesia, rash, flushing, facial swelling, urticaria, dyspnea, pruritus, and vomiting. Discontinue ADVATE if hypersensitivity symptoms occur and administer appropriate emergency treatment.

Neutralizing Antibodies

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

ADVERSE REACTIONS

Serious adverse reactions seen with ADVATE are hypersensitivity reactions, including anaphylaxis, and the development of high-titer inhibitors necessitating alternative treatments to factor VIII.
The most common adverse reactions observed in clinical trials (>5% of subjects) were pyrexia, headache, cough, nasopharyngitis, arthralgia, vomiting, upper respiratory tract infection, limb injury, nasal congestion, and diarrhea.

Click to read Full Prescribing Information.

MYPKFIT FOR ADVATE INTENDED USE

The myPKFiT software is intended for use by licensed healthcare professionals (HCPs) who are familiar with hemophilia care. The myPKFiT software can be used to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis for an individual patient 16 years of age and older and body weight of 45 kg or greater, using that patient’s age and body weight information and local laboratory FVIII one-stage clotting activity measurements of sparse samples collected from that patient.
A minimum of two sparse sampling points are required at the recommended 3-4 hours (± 30 minutes) and at 24-32 hours (±1 hour) post-infusion.
HCPs will also be able to evaluate various prophylaxis dose regimens tailored to an individual patient's needs and treatment plan.
The software output may be used to guide decisions on appropriate ADVATE dose and infusion intervals to maintain FVIII activity levels at or above a user specified minimum FVIII activity level between 1% to 3% above natural baseline for an individual patient in accordance with the FDA-approved dosing recommendations provided in the ADVATE Prescribing Information (PI).
myPKFiT should only be used to evaluate prophylactic dosing regimens for hemophilia A patients treated with ADVATE, as per the ADVATE Prescribing Information (PI).
myPKFiT for ADVATE is not indicated for the treatment of von Willebrand disease. MyPKFiT for ADVATE should not be used for patients who have developed neutralizing antibody (inhibitor) to FVIII products.

myPKFiT for ADVATE is Rx only. For safe and proper use of the myPKFiT software, please refer to the complete instructions for use in the User Manual.